IFNB1 and neoplasm: Having observed that the association between p19Arf/IFNβ gene transfer with the therapeutic dose of Dox does not further reduce tumor volume as compared to Dox alone, we next asked whether the benefit of this association would be maintained when using a sub-therapeutic dose of Dox, 10 mg/kg, and consequently ease induction of cardiotoxicity, a major side effect observed in the clinical setting.